 Connection
Allen Cohn to Carcinoma, Hepatocellular
This is a "connection" page, showing publications Allen Cohn has written about Carcinoma, Hepatocellular.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.398 |
|
|
|
-
Cohn AL, Myers JW, Mamus S, Deur C, Nicol S, Hood K, Khan MM, Ilegbodu D, Asmar L. A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2008 Aug; 26(4):381-6.
Score: 0.207
-
Kelley RK, Verslype C, Cohn AL, Yang TS, Su WC, Burris H, Braiteh F, Vogelzang N, Spira A, Foster P, Lee Y, Van Cutsem E. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol. 2017 03 01; 28(3):528-534.
Score: 0.096
-
Martin RC, Bruenderman E, Cohn A, Piperdi B, Miksad R, Geschwind JF, Goldenberg A, Sanyal A, Zigmont E, Babajanyan S, Foreman P, Mantry P, McGuire B, Gholam P. Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry. Am J Surg. 2017 Apr; 213(4):688-695.
Score: 0.095
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|